Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status

Journal of Pharmaceutical Sciences

Volumn 104, Issue 8, 2015, Pages 2619-2626

  Zhou, Jie ^a,b   Coles, Lisa D ^a,b   Kartha, Reena V ^a,b   Nash, Nardina ^b   Mishra, Usha ^a,b   Lund, Troy C ^b   Cloyd, James C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

glutathione (GSH); metabolism; metabolite kinetics; N acetylcysteine (NAC); pharmacodynamics; preclinical pharmacokinetics; prodrugs; redox ratio; stable label

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; STABLE ISOTOPE; ANTIOXIDANT; CARBON; NITROGEN; NOOTROPIC AGENT; PRODRUG;

ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; BRAIN HOMOGENATE; BRAIN TISSUE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG STABILITY; DRUG SYNTHESIS; ERYTHROCYTE; FEMALE; IN VIVO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PLASMA; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; AGONISTS; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NERVE CELL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; RANDOMIZATION; TISSUE DISTRIBUTION;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; BLOOD-BRAIN BARRIER; BRAIN; CARBON ISOTOPES; ERYTHROCYTES; FEMALE; GLUTATHIONE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MICE, INBRED C57BL; NEURONS; NITROGEN ISOTOPES; NOOTROPIC AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PRODRUGS; RANDOM ALLOCATION; TISSUE DISTRIBUTION;

EID: 84947044454     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24482     Document Type: Article

References (31)

1. Johnson WM, Wilson-Delfosse AL, Mieyal JJ,. 2012. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 4 (10): 1399-1440.
2. Nemeth I, Boda D,. 1994. Blood glutathione redox ratio as a parameter of oxidative stress in premature infants with IRDS. Free Radic Biol Med 16 (3): 347-353.
3. Petrillo S, Piemonte F, Pastore A, Tozzi G, Aiello C, Pujol A, Cappa M, Bertini E,. 2013. Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Mol Genet Metab 109 (4): 366-370.
4. Kosenko EA, Aliev G, Tikhonova LA, Li Y, Poghosyan AC, Kaminsky YG,. 2012. Antioxidant status and energy state of erythrocytes in Alzheimer dementia: Probing for markers. CNS Neurol Disord Drug Targets 11 (7): 926-932.
5. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA,. 2004. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80 (6): 1611-1617.
6. Bravi MC, Armiento A, Laurenti O, Cassone-Faldetta M, De Luca O, Moretti A, De Mattia G,. 2006. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 55 (5): 691-695.
7. Yao JK, Leonard S, Reddy R,. 2006. Altered glutathione redox state in schizophrenia. Dis Markers 22 (1-2): 83-93.
8. Chauhan A, Audhya T, Chauhan V,. 2012. Brain region-specific glutathione redox imbalance in autism. Neurochem Res 37 (8): 1681-1689.
9. Zitka O, Skalickova S, Gumulec J, Masarik M, Adam V, Hubalek J, Trnkova L, Kruseova J, Eckschlager T, Kizek R,. 2012. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol Lett 4 (6): 1247-1253.
10. Zhang C, Rodriguez C, Spaulding J, Aw TY, Feng J,. 2012. Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease. J Alzheimers Dis 28 (3): 655-666.
11. De Rosa SC, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA,. 2000. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 30 (10): 915-929.
12. Al-Tonbary Y, Al-Haggar M, El-Ashry R, El-Dakroory S, Azzam H, Fouda A,. 2009. Vitamin e and N-acetylcysteine as antioxidant adjuvant therapy in children with acute lymphoblastic leukemia. Adv Hematol 2009: 689639.
13. Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI,. 2011. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. Neurosci Lett 499 (3): 149-153.
14. Adair JC, Knoefel JE, Morgan N,. 2001. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57 (8): 1515-1517.
15. Berman AE, Chan WY, Brennan AM, Reyes RC, Adler BL, Suh SW, Kauppinen TM, Edling Y, Swanson RA,. 2011. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse. Ann Neurol 69 (3): 509-520.
16. Assous M, Had-Aissouni L, Gubellini P, Melon C, Nafia I, Salin P, Kerkerian-Le-Goff L, Kachidian P,. 2014. Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra. Neurobiol Dis 65C: 69-81.
17. van Zandwijk N,. 1995. N-acetylcysteine (NAC) and glutathione (GSH): Antioxidant and chemopreventive properties, with special reference to lung cancer. J Cell Biochem Suppl 22: 24-32.
18. Nakagawa Y, Suzuki T, Nakajima K, Inomata A, Ogata A, Nakae D,. 2014. Effects of N-acetyl-L-cysteine on target sites of hydroxylated fullerene-induced cytotoxicity in isolated rat hepatocytes. Arch Toxicol 88 (1): 115-126.
19. Uttamsingh V, Baggs RB, Krenitsky DM, Anders MW,. 2000. Immunohistochemical localization of the acylases that catalyze the deacetylation of N-acetyl-L-cysteine and haloalkene-derived mercapturates. Drug Metab Dispos 28 (6): 625-632.
20. Raftos JE, Whillier S, Chapman BE, Kuchel PW,. 2007. Kinetics of uptake and deacetylation of N-acetylcysteine by human erythrocytes. Int J Biochem Cell Biol 39 (9): 1698-1706.
21. Ventura P, Panini R, Pasini MC, Scarpetta G, Salvioli G,. 1999. N-acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol Res 40 (4): 345-350.
22. Whillier S, Raftos JE, Chapman B, Kuchel PW,. 2009. Role of N-acetylcysteine and cystine in glutathione synthesis in human erythrocytes. Redox Rep 14 (3): 115-124.
23. Radtke KK, Coles LD, Mishra U, Orchard PJ, Holmay M, Cloyd JC,. 2012. Interaction of N-acetylcysteine and cysteine in human plasma. J Pharm Sci 101 (12): 4653-4659.
24. Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Oz G, Cloyd JC, Tuite PJ,. 2013. N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol 36 (4): 103-106.
25. Nedelman JR, Jia X,. 1998. An extension of Satterthwaite's approximation applied to pharmacokinetics. J Biopharm Stat 8 (2): 317-328.
26. Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C,. 2001. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21 (1): 15-23.
27. De Flora S, Bennicelli C, Camoirano A, Serra D, Romano M, Rossi GA, Morelli A, De Flora A,. 1985. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis 6 (12): 1735-1745.
28. Pendyala L, Creaven PJ,. 1995. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev 4 (3): 245-251.
29. McLellan LI, Lewis AD, Hall DJ, Ansell JD, Wolf CR,. 1995. Uptake and distribution of N-acetylcysteine in mice: Tissue-specific effects on glutathione concentrations. Carcinogenesis 16 (9): 2099-2106.
30. Wade LA, Brady HM,. 1981. Cysteine and cystine transport at the blood-brain barrier. J Neurochem 37 (3): 730-734.
31. Jones DP, Go YM, Anderson CL, Ziegler TR, Kinkade, Jr. JM, Kirlin WG,. 2004. Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control. FASEB J 18 (11): 1246-1248.